Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Bauer, Alison K ^a   Fostel, Jennifer ^b   Degraff, Laura M ^b   Rondini, Elizabeth A ^a   Walker, Christopher ^b   Grissom, Sherry F ^b   Foley, Julie ^b   Kleeberger, Steven R ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; OSTEOPONTIN; TOLL LIKE RECEPTOR 4; BUTYLCRESOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL COUNT; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CHRONIC DISEASE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CANCER STAGING; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; REPRODUCIBILITY; TUMOR GENE;

MURINAE; MUS;

ANIMALS; BUTYLATED HYDROXYTOLUENE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; NEOPLASM STAGING; PNEUMONIA; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 71549130421     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-107     Document Type: Article

References (55)

1. Schottenfeld D. Etiology and Epidemiology of Lung Cancer. Lung Cancer- Principles and Practice 2000, 367-388. Philadelphia: Lippincott Williams and Wilkins, Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, 2.
2. Bauer AK, Malkinson AM, Kleeberger SR. Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Lung Cell Mol Physiol 2004, 287:L685-703. 10.1152/ajplung.00223.2003, 15355860.
3. Cohen BH, Diamond EL, Graves CG, Kreiss P, Levy DA, Menkes HA, Permutt S, Quaskey S, Tockman MS. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977, 2:523-526. 10.1016/S0140-6736(77)90663-8, 95731.
4. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999, 149:13-20.
5. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 1993, 22:976-982. 10.1093/ije/22.6.976, 8144310.
6. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. ExpLung Res 1998, 24:541-555.
7. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM. Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 2001, 27:197-216. 10.1080/019021401300053948, 11293324.
8. Malkinson AM, Radcliffe RA, Bauer AK. Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice. Carcinogenesis 2002, 23:411-417. 10.1093/carcin/23.3.411, 11895855.
9. Malkinson AM, Koski KM, Evans WA, Festing MF. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res 1997, 57:2832-2834.
10. Witschi H, Malkinson AM, Thompson JA. Metabolism and pulmonary toxicity of butylated hydroxytoluene. Metabolic Activation and Toxicity of Chemical Agents to Lung Tissue and Cells 1993, 185-212. United Kingdom: Pergamon Press, Gram TE.
11. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088. 10.1126/science.282.5396.2085, 9851930.
12. Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE. Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol 2000, 22:620-627.
13. Zhang X, Shan P, Qureshi S, Homer R, Medzhitov R, Noble PW, Lee PJ. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 2005, 175:4834-4838.
14. Hollingsworth JW, Whitehead GS, Lin KL, Nakano H, Gunn MD, Schwartz DA, Cook DN. TLR4 signaling attenuates ongoing allergic inflammation. J Immunol 2006, 176:5856-5862.
15. Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, Li W, Wernli KJ, Fitzgibbons ED, Thomas DB, Checkoway H. Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst 2007, 99:357-364. 10.1093/jnci/djk063, 17341727.
16. Laakkonen A, Kyyronen P, Kauppinen T, Pukkala EI. Occupational exposure to eight organic dusts and respiratory cancer among Finns. Occup Environ Med 2006, 63:726-733. 10.1136/oem.2005.025825, 2077994, 16601013.
17. Mastrangelo G, Grange JM, Fadda E, Fedeli U, Buja A, Lange JH. Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. Am J Epidemiol 2005, 161:1037-1046. 10.1093/aje/kwi138, 15901624.
18. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF, El-Omar EM. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912. 10.1053/j.gastro.2006.12.026, 17324405.
19. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, Elmets CA. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008, 68:615-622. 10.1158/0008-5472.CAN-07-5219, 18199559.
20. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, Kleeberger SR. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005, 97:1778-1781.
21. Vogel SN, Wax JS, Perera PY, Padlan C, Potter M, Mock BA. Construction of a BALB/c congenic mouse, C.C3H-Lpsd, that expresses the Lpsd allele: analysis of chromosome 4 markers surrounding the Lps gene. Infect Immun 1994, 62:4454-4459. 303130, 7927709.
22. Brown LM, Malkinson AM, Rannels DE, Rannels SR. Compensatory lung growth after partial pneumonectomy enhances lung tumorigenesis induced by 3-methylcholanthrene. Cancer Res 1999, 59:5089-5092.
23. Bauer AK, Dwyer-Nield LD, Malkinson AM. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis 2000, 21:543-550. 10.1093/carcin/21.4.543, 10753183.
24. Hernandez LG, Forkert PG. Inhibition of vinyl carbamate-induced lung tumors and Kras2 mutations by the garlic derivative diallyl sulfone. Mutat Res 2009, 662:16-21.
25. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005, 167:1763-1775. 1613183, 16314486.
26. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002, 26:175-182.
27. Katoh Y, Katoh M. Canonical WNT signaling pathway and human AREG. Int J Mol Med 2006, 17:1163-1166.
28. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila Pa) 2008, 1:201-207.
29. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E, Sasazuki T. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 2000, 60:6886-6889.
30. Toyoda H, Komurasaki T, Ikeda Y, Yoshimoto M, Morimoto S. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 1995, 377:403-407. 10.1016/0014-5793(95)01403-9, 8549764.
31. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschop MH, Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007, 117:2877-2888. 10.1172/JCI31986, 1964510, 17823662.
32. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652. 10.1158/1078-0432.CCR-04-2013, 16000556.
33. Cho YM, Lewis DA, Koltz PF, Richard V, Gocken TA, Rosol TJ, Konger RL, Spandau DF, Foley J. Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. J Endocrinol 2004, 181:179-190. 10.1677/joe.0.1810179, 15072578.
34. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV, Broxmeyer HE, Charo IF. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997, 100:2552-2561. 10.1172/JCI119798, 508456, 9366570.
35. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 2007, 170:693-708. 10.2353/ajpath.2007.060566, 1851863, 17255336.
36. Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, Mackowiak II, Mori CM, da Silva TC, Oloris SC, Garate AP, Massironi SM, Yamasaki H, Dagli ML. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Carcinogenesis 2004, 25:1973-1982. 10.1093/carcin/bgh193, 15166089.
37. Johnson LN, Koval M. Cross-talk between pulmonary injury, oxidant stress, and gap junctional communication. Antioxid Redox Signal 2009, 11:355-367. 10.1089/ars.2008.2183, 18816185.
38. Manenti G, Galbiati F, Noci S, Dragani TA. Outbred CD-1 mice carry the susceptibility allele at the pulmonary adenoma susceptibility 1 (Pas1) locus. Carcinogenesis 2003, 24:1143-1148. 10.1093/carcin/bgg065, 12807761.
39. Manenti G, De Gregorio L, Pilotti S, Falvella FS, Incarbone M, Ravagnani F, Pierotti MA, Dragani TA. Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis. Carcinogenesis 1997, 18:1917-1920. 10.1093/carcin/18.10.1917, 9364000.
40. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Keller ET, Yao Z, Zhang J. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 2007, 121:724-733. 10.1002/ijc.22704, 17390372.
41. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
42. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, Murphy SE, Yang P, Pesatori AC, Consonni D, Bertazzi PA, Wacholder S, Shih JH, Caporaso NE, Jen J. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008, 3:e1651. 10.1371/journal.pone.0001651, 2249927, 18297132.
43. Lee S, Kang J, Cho M, Seo E, Choi H, Kim E, Kim J, Kim H, Kang GY, Kim KP, Park YH, Yu DY, Yum YN, Park SN, Yoon DY. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009, 34:161-172.
44. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, Sridhar S, Beamis J, Lamb C, Anderson T, Gerry N, Keane J, Lenburg ME, Brody JS. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007, 13:361-366. 10.1038/nm1556, 17334370.
45. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008, 26:877-883. 10.1200/JCO.2007.13.1516, 18281660.
46. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835. 10.1016/j.cell.2005.03.032, 15960971.
47. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
48. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167. 10.1126/science.1101637, 15284455.
49. Jayachandran G, Sazaki J, Nishizaki M, Xu K, Girard L, Minna JD, Roth JA, Ji L. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res 2007, 67:10379-10388. 10.1158/0008-5472.CAN-07-0677, 17974981.
50. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R. Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. Br J Cancer 2001, 84:813-818. 10.1054/bjoc.2000.1676, 2363807, 11259097.
51. Holth LT, Thorlacius AE, Reeves R. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. DNA Cell Biol 1997, 16:1299-1309. 10.1089/dna.1997.16.1299, 9407002.
52. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001, 154:459-468. 10.1083/jcb.200103103, 2150768, 11470832.
53. Tsuneoka M, Koda Y, Soejima M, Teye K, Kimura H. A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem 2002, 277:35450-35459. 10.1074/jbc.M204458200, 12091391.
54. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004, 90:1679-1685. 10.1038/sj.bjc.6601768, 2409696, 15083203.
55. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664. 10.1074/jbc.M705064200, 17636266.